14 Result(s)

Article

Remission of severe cold agglutinin disease Rituximab therapy

N Layios, E Van Den Neste, E Jost, V Deneys, JM Scheiff, A Ferrant in Leukemia (2001)

Article

Complex karyotype and absence of mutation in the c-kit receptor in aggressive mastocytosis presenting with pelvic osteolysis, eosinophilia and brain damage

Aggressive mastocytosis is a form of systemic mast cell disease (SMCD) characterized by organ infiltration, bone lesions, eosinophilia and lymphadenopathies. Here we report a patient with unusual clinical fea...

E. Jost, L. Michaux, M. Vanden Abeele, B. Boland, D. Latinne… in Annals of Hematology (2001)

Article

DNA methylation changes in multiple myeloma

Using a candidate gene approach, we analyzed the methylation status of the promoter-associated CpG islands of 11 well-characterized tumor suppressor genes by methylation-specific polymerase chain reaction in f...

O Galm, S Wilop, J Reichelt, E Jost, G Gehbauer, J G Herman, R Osieka in Leukemia (2004)

Article

Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders

An acquired autoactivating mutation with a V617F amino-acid substitution in the JAK2 tyrosine kinase is frequently found in BCR/ABL-negative myeloproliferative disorders (MPD). Hypermethylation of CpG islands wit...

E Jost, N do Ó, E Dahl, C E Maintz, P Jousten, L Habets, S Wilop, J G Herman… in Leukemia (2007)

Article

Contrast enhancement in multidetector-row computed tomography (MDCT) of the abdomen: intraindividual comparison of contrast media containing 300 mg versus 370 mg iodine per ml

The purpose of this study was to intraindividually evaluate the difference in intraluminal vessel and parenchyma contrast enhancement of two different iodine concentrations in multidetector-row computed tomogr...

F. F. Behrendt, A. H. Mahnken, S. Keil, M. Das, C. Hohl, D. Bauer… in European Radiology (2008)

Article

SOCS2: inhibitor of JAK2V617F-mediated signal transduction

Janus kinase 2 (JAK2)V617F-activating mutations (JAK2mu) occur in myeloproliferative disorders (MPDs) and myelodysplastic syndromes (MDSs). Cell lines MB-02, MUTZ-8, SET-2 and UKE-1 carry JAK2V617F and derive fro...

H Quentmeier, R Geffers, E Jost, R A F MacLeod, S Nagel, S Röhrs, J Romani… in Leukemia (2008)

Article

Hypercholesterolemia and its association with enhanced stem cell mobilization and harvest after high-dose cyclophosphamide+G-CSF

High-dose chemotherapy with autologous peripheral blood SCT is a common treatment option in several hematological and non-hematological malignancies. So far, prediction of successful stem cell mobilization and...

M Crysandt, R-D Hilgers, S von Hobe, A Eisert, E Jost… in Bone Marrow Transplantation (2011)

Article

Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR–ABL-positive cells

Persistent activation of the Abl tyrosine kinase in the BCR–ABL fusion protein is the major cause of chronic myeloid leukemia (CML). Among many other substrates BCR–ABL phosphorylates STAT5 and Src family kina...

N Chatain, P Ziegler, D Fahrenkamp, E Jost, R Moriggl, H Schmitz-Van de Leur… in Oncogene (2013)

Article

Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians

Philadelphia-negative myeloproliferative neoplasms (MPN) comprise a heterogeneous group of chronic hematological malignancies with significant variations in clinical characteristics. Due to the long survival a...

A. Kaifie, S. Isfort, N. Gattermann, W. Hollburg, M. Klausmann… in Annals of Hematology (2016)

Article

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis

Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is repor...

R F Schlenk, F Stegelmann, A Reiter, E Jost, N Gattermann, H Hebart, C Waller… in Leukemia (2017)